Advertisement DNA2.0 enters into strategic alliance with Aldevron - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

DNA2.0 enters into strategic alliance with Aldevron

DNA2.0 and Aldevron have entered into a collaboration agreement to develop enhanced gene synthesis algorithms for baculovirus protein expression in insect cells.

Under the agreement, DNA2.0 will use its GeneGPS technology and Aldevron will use its protein production experience for improving recombinant protein production in insect cell culture.

Insect cell expression systems permits folding, oligomerization and other post-translational modifications that are identical to those that occur in mammalian cells.

By increasing the productivity from insect cell culture, the collaboration will further benefit drug discovery research and commercial therapeutic protein production.

Aldevron vice president Tom Foti said the company’s expertise in protein expression and production compliments DNA2.0’s gene design and expression optimization technology.

"Through this collaboration, we will be able to provide our clients an improved method for producing high quality proteins with increased yields — all while saving them crucial time and money," Foti added.

DNA2.0 cofounder and CEO Jeremy Minshull said, "By combining our patented GeneGPS technology — which has been proven to increase protein expression up to 100-fold — with Aldevron’s strength in large scale protein production, I’m confident that we will develop a best-in-class solution for insect cell culture."